Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Zhen Ruan, Huimin Zou, Qing Lei, Carolina Oi Lam Ung, Honghao Shi & Hao Hu. (2022) Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review. Expert Review of Pharmacoeconomics & Outcomes Research 22:4, pages 555-574.
Read now
Read now
Beatriz Rodriguez-Sanchez, Isaac Aranda-Reneo, Juan Oliva-Moreno & Julio Lopez-Bastida. (2021) Assessing the Effect of Including Social Costs in Economic Evaluations of Diabetes-Related Interventions: A Systematic Review. ClinicoEconomics and Outcomes Research 13, pages 307-334.
Read now
Read now
Articles from other publishers (12)
Gihan Hamdy Elsisi, Ayman Afify, Ashraf Abgad, Ibtissam Zakaria, Nabil Nasif, Hani Naiem Ibrahim, Nabil Raafat & João L. Carapinha. (2022) A budget impact analysis of substituting sitagliptin with liraglutide in type 2 diabetes from a private health insurance perspective in Egypt. Cost Effectiveness and Resource Allocation 20:1.
Crossref
Crossref
Bhavani Shankara Bagepally, Usa Chaikledkaew, Nathorn Chaiyakunapruk, John Attia & Ammarin Thakkinstian. (2022) Meta-analysis of economic evaluation studies: data harmonisation and methodological issues. BMC Health Services Research 22:1.
Crossref
Crossref
Francisco J. Barrera, Freddy JK. Toloza, Oscar J. Ponce, Jorge A. Zuñiga-Hernandez, Larry J. Prokop, Nilay D. Shah, Gordon Guyatt, Rene Rodriguez-Gutierrez & Victor M. Montori. (2020) The validity of cost-effectiveness analyses of tight glycemic control. A systematic survey of economic evaluations of pharmacological interventions in patients with type 2 diabetes. Endocrine 71:1, pages 47-58.
Crossref
Crossref
J. Pöhlmann, K. Norrbacka, K. S. Boye, W. J. Valentine & H. Sapin. (2020) Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy. The European Journal of Health Economics 21:8, pages 1179-1196.
Crossref
Crossref
Bhavani Shankara Bagepally, Usa Chaikledkaew, Yogesh Krishnarao Gurav, Thunyarat Anothaisintawee, Sitaporn Youngkong, Nathorn Chaiyakunapruk, Mark McEvoy, John Attia & Ammarin Thakkinstian. (2020) Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies. BMJ Open Diabetes Research & Care 8:1, pages e001020.
Crossref
Crossref
B. Guerci, B. Charbonnel, P. Gourdy, S. Hadjadj, H. Hanaire, M. Marre & B. Vergès. (2019) Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings. Diabetes & Metabolism 45:6, pages 528-535.
Crossref
Crossref
Kasper S Madsen, Pernille Kähler, Lise Katrine Aronsen Kähler, Sten Madsbad, Filip Gnesin, Maria-Inti Metzendorf, Bernd Richter & Bianca Hemmingsen. (2019) Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Dongzhe Hong, Lei Si, Minghuan Jiang, Hui Shao, Wai-kit Ming, Yingnan Zhao, Yan Li & Lizheng Shi. (2019) Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review. PharmacoEconomics.
Crossref
Crossref
Néboa Zozaya, Margarita Capel, Susana Simón & Alfonso Soto-González. (2019) A systematic review of economic evaluations in non-insulin antidiabetic treatments for patients with type 2 diabetes mellitus. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 2019, pages 228424031987657.
Crossref
Crossref
Anthony H. Barnett, Simon Arnoldini, Barnaby Hunt, Gowri Subramanian & Christina Stentoft Hoxer. (2018) Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis. Diabetes, Obesity and Metabolism 20:8, pages 1921-1927.
Crossref
Crossref
Barnaby Hunt, Gabriela Vega-Hernandez, William J. Valentine & Nana Kragh. (2017) Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting. Diabetes, Obesity and Metabolism 19:6, pages 842-849.
Crossref
Crossref
Pedro Mezquita-Raya, Antonio Ramírez de Arellano, Nana Kragh, Gabriela Vega-Hernandez, Johannes Pöhlmann, William J. Valentine & Barnaby Hunt. (2017) Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain. Diabetes Therapy 8:2, pages 401-415.
Crossref
Crossref